(19)
(11) EP 3 247 724 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.04.2025 Bulletin 2025/16

(45) Mention of the grant of the patent:
12.03.2025 Bulletin 2025/11

(21) Application number: 16700518.0

(22) Date of filing: 12.01.2016
(51) International Patent Classification (IPC): 
C07K 16/24(2006.01)
(52) Cooperative Patent Classification (CPC):
A01K 67/0278; A01K 2217/072; A01K 2217/15; A01K 2227/105; A01K 2267/01; A61K 2039/505; C07K 2317/565; C07K 2317/569; C07K 2317/92; C07K 16/244; A61P 37/02; A61P 31/00; A61P 37/06; A61P 37/08
(86) International application number:
PCT/GB2016/050070
(87) International publication number:
WO 2016/113557 (21.07.2016 Gazette 2016/29)

(54)

IL-17A BINDING PROTEINS

IL-17A-BINDENDE PROTEINE

PROTÉINES DE LIAISON À IL-17A

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 12.01.2015 GB 201500463

(43) Date of publication of application:
29.11.2017 Bulletin 2017/48

(60) Divisional application:
25162857.4

(73) Proprietor: Crescendo Biologics Limited
Cambridge CB1 2JH (GB)

(72) Inventors:
  • EDWARDS, Bryan
    Cambridge Cambridgeshire CB22 3AT (GB)
  • LASHMAR, Ulla
    Cambridge Cambridgeshire CB22 3AT (GB)
  • MCGUINNESS, Brian
    Cambridge Cambridgeshire CB22 3AT (GB)
  • ROMANOS, Mike
    Cambridge Cambridgeshire CB22 3AT (GB)
  • SANDAL, Thomas
    Cambridge Cambridgeshire CB22 3AT (GB)
  • TENG, Yumin
    Cambridge Cambridgeshire CB22 3AT (GB)

(74) Representative: Appleyard Lees IP LLP 
15 Clare Road
Halifax HX1 2HY
Halifax HX1 2HY (GB)


(56) References cited: : 
WO-A1-2007/149032
WO-A1-2013/063110
WO-A2-2010/102251
 WO-A1-2012/156219
WO-A2-2008/021156
   
  • MATTHEW ROE: "Superior human single domain VH antibody fragments from a transgenic mouse", BIOPHARMADEALMAKERS, 12 April 2013 (2013-04-12), pages B23, XP055254756, Retrieved from the Internet <URL:http://www.crescendobiologics.com/uploads/news/id11/Nature Biopharma Dealmakers April 2013.pdf> [retrieved on 20160302]
  • VANHEUSDEN KATRIEN ET AL: "Pre-Clinical Proof-Of-Concept Of ALX-0761, a Nanobody (R) Neutralizing Both IL-17A and F In a Cynomolgus Monkey Collagen Induced Arthritis Model", ARTHRITIS & RHEUMATISM, WILEY INTERSCIENCE, US, vol. 65, 30 September 2013 (2013-09-30), pages S543, XP009511645, ISSN: 0004-3591, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131>
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).